ALKEM2023-10-012023-12-31 ALKEM2023-10-012023-12-31 ALKEM2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member ALKEM2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member ALKEM2023-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 539523 ALKEM NOTLISTED Alkem Laboratories Limited Equity 2023-04-01 2024-03-31 2024-02-09 2024-02-01 INR Millions Third quarter 11:00:00 13:00:00 2024-02-09 2024-02-09 Not applicable Single segment The Company is exclusively engaged in pharmaceutical business 2023-10-01 2023-12-31 Unaudited Standalone 24945900000.00 956600000.00 25902500000.00 7007300000.00 3311800000.00 -274100000.00 4076300000.00 211100000.00 581200000.00 5132000000.00 20045600000.00 5856900000.00 -513100000.00 5343800000.00 904600000.00 -603100000.00 301500000.00 0.00 5042300000.00 0.00 0.00 0.00 0.00 5042300000.00 -15600000.00 5026700000.00 0.00 0.00 239100000.00 2 42.17 42.17 0.00 0.00 42.17 42.17 1. The above unaudited standalone financial results of the Company were reviewed and recommended by the Audit Committee on 8 February 2024 and subsequently approved by the Board of Directors at its meeting held on 9 February 2024. The auditors have issued an unmodified report on the financial results for the quarter and nine months ended 31 December 2023. 2. During the current quarter, a cyber security incident which compromised business email IDs of certain employees at one of the subsidiaries resulted in a fraudulent transfer of funds of approximately Rs. 513.1 Million. The Company employed independent external agencies to investigate the incident and pursuant to this, the Company concluded that the impact of the incident did not extend beyond the above amount which is reported under 'Exceptional items'. 3. The Board of Directors at its meeting held on 9 February 2024 have declared an interim dividend of Rs 35 (Rupees Thirty five only) per equity share (1750% on the face value of Rs 2 each) for the financial year ending 31 March 2024. 4. The Company operates in one reportable business segment i.e. Pharmaceuticals , accordingly no separate disclosure of segment has been made. Single segment 2023-04-01 2023-12-31 Unaudited Standalone 73823500000.00 2222000000.00 76045500000.00 20972200000.00 8587400000.00 -799800000.00 12168700000.00 612300000.00 1752500000.00 17318900000.00 60612200000.00 15433300000.00 -513100000.00 14920200000.00 2558700000.00 -1860300000.00 698400000.00 0.00 14221800000.00 0.00 0.00 0.00 0.00 14221800000.00 -47000000.00 14174800000.00 0.00 0.00 239100000.00 2 118.95 118.95 0.00 0.00 118.95 118.95 Other Expenses 5132000000.00 Other Expenses 17318900000.00 -24100000.00 -72300000.00 -8500000.00 -25300000.00